Aura Biosciences to Participate in Upcoming Investor Conferences
08 Mayo 2024 - 6:00AM
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing precision immunotherapies to treat
solid tumors designed to preserve the function of the organ with
cancer, today announced that Elisabet de los Pinos, PhD,
Chief Executive Officer, will participate in the following upcoming
investor conferences:
- The Citizens JMP Life Sciences Conference on Monday,
May 13, 2024.Fireside Chat at 9:00 a.m. ET.
- TD Cowen 5th Annual Oncology
Innovation Summit on Wednesday, May 29, 2024.Fireside Chat
at 10:00 a.m. ET.
The live webcasts of both fireside chats will be
available on the “Investors & Media” page under the “Events
& Presentations” section of the Company’s website
at https://ir.aurabiosciences.com/events-and-presentations,
where a replay of the webcast will be archived for 90 days
following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage
biotechnology company developing precision immunotherapies to treat
solid tumors designed to preserve the function of the organ with
cancer. Our lead candidate bel-sar is in late-stage clinical
development for the treatment of patients with primary choroidal
melanoma, and other ocular oncology indications as well as in
early-stage clinical development in bladder cancer. We are
evaluating the safety and efficacy of bel-sar as a potential
vision-sparing therapy in an ongoing global Phase 3 CoMpass trial
for the first-line treatment of adult patients with early-stage
choroidal melanoma. Bel-sar is also being evaluated in additional
solid cancers, including bladder cancer. Our mission is to develop
vision and organ-sparing therapies to improve patient outcomes in
cancer. Aura is headquartered in Boston, MA. For more information,
visit aurabiosciences.com. Visit us @AuraBiosciences and on
LinkedIn.
Investors and Media:
Alex DasallaHead of Investor Relations and
Corporate Communicationsadasalla@aurabiosciences.com
Source: Aura Biosciences, Inc.
Aura Biosciences (NASDAQ:AURA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aura Biosciences (NASDAQ:AURA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024